- : Aotearoa 4 Assange
- : 20/02/2024
Statement: Spokesperson: Aotearoa 4 Assange, Matt Ó Branáin.
Tomorrow, February 20 in London, Australian Journalist Julian Assange faces perhaps his final chance to avoid extradition to the U.S.
I am a Free Assange activist from New Zealand, who has been following the case almost full time for 4.5 years, and campaigning through Europe and the UK since October 2022, since I inspired a human chain of 8,000 around the British Parliament to free Julian.
Tomorrow I will be outside the Royal Courts of Justice in London as Julian faces his last chance to avoid extradition to the U.S. I will be staging a Photo Action outside along with Italian artist Davide Dormino, inviting the public to stand on a chair and make a photograph to share.
What has surprised me is I have been granted last-minute access to monitor the hearings remotely, a privilege not granted to many journalists, excluding almost anyone outside England and Wales, and major media organisations in Australia and the U.S. including Fox News.
Julian faces a 175 year sentence for activities described as ‘common journalistic practices’ by the editors of the five major international Newspapers he collaborated with on the 2010 publications he is indicted for.
The charges are unprecedented. The U.S. seeks to prosecute him for publishing leaked evidence of war crimes in Iraq, which are credited with ending the illegal invasion. If ending a war with truthful journalism is a crime, what chance do we have of preventing further atrocities? Why has this case dragged on so long when every major Human Rights group has called for his freedom? Why has a case of this magnitude not yet provoked more outcry from the media and the public?
In Australia at least it has reached a crescendo. The Australian Parliament last week voted with a two thirds majority to demand the U.S. and UK free Julian. Polls show as much as 90% of the public think he should be freed.
With such a clear mandate, it would seem profoundly unwise for the US and UK to risk snubbing such a clear request from such a vital ally?
The shared values of our long-standing partnership with the U.S. and UK are what is on trial. Because what do we need the might of the U.S. Army to defend us from exactly, if not from those that jail our journalists for revealing their war crimes?
Matt Ó Branáin.
Spokesperson: Aotearoa 4 Assange
- : Matt Ó Branáin
- : Spokesperson: Aotearoa 4 Assange
- : Matt.O.Branain@protonmail.com
- : 447849825761
- : https://www.a4a.nz/
Alimetry Secures CPT III Reimbursement Code for the Gastric Alimetry Test and Announces Positive Clinical Study Results
- : Alimetry Ltd
- : 12/02/2024
Alimetry, a gastrointestinal medtech and digital health start-up, announced today the creation of a new American Medical Association (AMA) Current Procedural Terminology (CPT) III code for Body Surface Gastric Mapping, which will describe its Gastric Alimetry test.
The new CPT III code highlights the growing recognition of Body Surface Gastric mapping and Gastric Alimetry as a significant advance in the diagnosis and management of chronic gastric conditions, including functional dyspepsia, gastroparesis, and chronic nausea and vomiting syndrome. Together, these disorders affect >10% of the US population.
CEO, Greg O’Grady, a Professor of Surgery and co-founder of Alimetry, said: “Obtaining a CPT III code is a key milestone for Alimetry. Gastric Alimetry is emerging as a next-generation test for patients suffering chronic gastric symptoms, with excellent early adoption in over 30 hospitals and clinics. The new AMA code will accelerate our mission to achieve widespread access for US patients suffering from these disabling disorders.”
The CPT III code comes on the back of Alimetry’s 3rd 510k clearance from the US Food and Drug Administration (FDA) in just 2 years for the Gastric Alimetry System. The latest FDA clearance introduced new features to aid in the diagnosis of gut hypersensitivity and common ‘Gut-Brain-Axis’ disorders, which are often linked to mental wellbeing. Chief Medical Officer Professor Chris Andrews stated: “Gastric symptoms can be complex, and are often a diagnostic challenge. Gastric Aimetry combines a wearable sensor with an App- based digital health profiling tool, providing an increasingly powerful feature set that can greatly simplify the diagnostic process. The cloud-based platform also enables us to rapidly learn and improve test performance based on banked data, with an increasing focus on applications in AI.”
In addition to the new CPT Code, Alimetry also announced positive clinical study results, published this month in the American Journal of Gastroenterology. In the study discussion, the authors concluded that “Gastric Alimetry identified 2.7x more specific patient categories than gastric emptying testing [a standard of care test], with limited overlap between each diagnostic modality, offering a valuable new option in the diagnostic work up of patients with chronic gastroduodenal symptoms”. In addition, Gastric Alimetry data was reported to show “improved correlation with symptoms and psychometrics” compared to existing clinical and research tools.
Gastric Alimetry is commercially available in the United States, the UK and New Zealand. The study article can be accessed in this hyperlink
About Gastric Alimetry
The Gastric Alimetry test measures gastric electrophysiology non-invasively in a clinical setting. Recordings are taken before and after a standard meal, while patients simultaneously log their symptoms into the Gastric Alimetry App. The system performs a high-resolution recording of digestive patterns from the skin surface and delivers clinical reports via the cloud to inform the diagnosis of gastric diseases and support personalized therapy. The Gastric Alimetry system is indicated as an aid to diagnosis of various gastric disorders, including functional dyspepsia, gastroparesis and chronic nausea and vomiting disorders, which affect >10% of the US population and impact billions of dollars in healthcare expenses.
About AMA CPT III Codes
AMA CPT III codes are temporary codes assigned to emerging medical technologies and procedures. These codes facilitate data collection and assessment, aiding in the validation and reimbursement of new services. Obtaining a CPT III code, such as for Alimetry’s Gastric Alimetry test, is a vital step towards recognizing its clinical relevance and supporting its integration into healthcare practices. The new CPT III code number is 0868T and it is effective from July 1, 2024.
Alimetry is a medtech and digital health start-up focused on improving the care of patients with chronic gastrointestinal symptoms. Spun out of the University of Auckland in 2019 from a centre of excellence in digestive diseases, the company was founded by Professor Gregory O’Grady (CEO) and Dr. Armen Gharibans (CTO), leveraging a decade of award-winning science. Alimetry is dedicated to advancing gastrointestinal health through innovative diagnostic solutions, aiming to enhance the quality of life for patients worldwide. For more information see www.alimetry.com
Hanie Yee, Chief Commercial Officer, Alimetry Hanie@alimetry.com
NZ +64 (0)21 651226 US +1 (657) 267 1082
- Alimetry CPT III Press Release 12th Feb 2024 (1)
- : Hanie Yee
- : Chief Commercial Officer, Alimetry
- : Hanie@alimetry.com
- : 64021651226
- : https://www.alimetry.com
- US Phone Number: +1 (657) 267 1082 | https://nz.linkedin.com/company/alimetry-ltd | @alimetry_ltd